Naveen Pemmaraju: Rusfertide for patients with phlebotomy-dependent Polycythemia Vera (PV)

Naveen Pemmaraju posted on LinkedIn:

”Honored to share our brand new paper recently published in The New England Journal of Medicine, NEJM Group. Rusfertide , the first-in-class Hepcidin Mimetic, for patients with phlebotomy-dependent Polycythemia Vera (PV) : phase 2 results for the REVIVE clinical trial.”

Read further.
Source: Naveen Pemmaraju/LinkedIn

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.

His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.

He has been named MDACC’s, Department of Leukemia, Inaugural Director of BPDCN Program, in 2020, which is one of the world’s most active BPDCN research programs. Dr. Pemmaraju is the recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. He is a well-known social media influencer and advocate.